The IL3 Knockout SK-OV-3 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population generated from the SK-OV-3 human ovarian adenocarcinoma cell line. This product features targeted disruption of the IL3 gene, which encodes interleukin-3, a key hematopoietic growth factor. The polyclonal nature provides a heterogeneous mixture of gene-edited cells, offering a robust loss-of-function model for functional studies. CRISPR/Cas9-mediated gene disruption abolishes IL-3 expression, facilitating precise investigation of IL-3-dependent signaling in a solid tumor context.
The parental SK-OV-3 cell line, derived from a human ovarian adenocarcinoma, exhibits epithelial morphology and is a well-established model for ovarian cancer research. These cells are frequently used in tumor biology studies, drug sensitivity assays, and xenograft experiments. The epithelial origin makes them suitable for examining how hematopoietic cytokines like IL-3 may influence carcinoma behavior, providing a consistent platform for gene-editing applications.
IL-3 is a pleiotropic cytokine signaling through a heterodimeric receptor composed of IL-3R?? (CD123) and CSF2RB (??c). Ligand binding activates JAK2, leading to phosphorylation of STAT5, and triggers the MAPK/ERK and PI3K-AKT pathways. Downstream targets include AKT, ERK, Bcl-xL, and Cyclin D, which regulate proliferation, survival, and differentiation. Upstream regulators encompass T-cell receptor activation, Fc??RI signaling, cytokines such as IL-1?? and TNF-??, and transcription factors NF-AT, AP-1, and NF-??B. Adaptor proteins Gab2 and SHP2 link receptor engagement to PI3K activation, underscoring the network??s complexity.
In SK-OV-3 cells, IL3 knockout permits dissection of IL-3??s role in ovarian cancer pathophysiology. While IL-3 is primarily hematopoietic, ectopic expression or paracrine sources in the tumor microenvironment may promote cancer cell proliferation, survival, or migration. By eliminating IL-3, researchers can assess alterations in downstream effectors like STAT5 and AKT, and evaluate how stromal IL-3 might influence epithelial tumor cells. This model is valuable for studying cytokine-mediated crosstalk in the ovarian cancer microenvironment.
Key applications include investigating IL-3 signaling in ovarian cancer, tumor microenvironment interactions, and paracrine effects on proliferation and survival. Suitable assays encompass Western blotting and RT-qPCR for expression analysis, MTT proliferation assay, Annexin V apoptosis assessment, phospho-STAT5/ERK pathway analysis, and transwell migration assays. Drug response studies may also be performed to explore IL-3-mediated modulation of therapy sensitivity. For more information, please contact Ascent Research.
